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Abstract  
Objective: This study was designed to evaluate the effect of letrozole 2.5 mg, an aromatase inhibitor, on 
the sperm retrieval rate (SRR) by the testicular sperm extraction (TESE) procedures that was done for 
the treatment of males with non-obstructive azoospermia (NOA). 
Materials and methods: Data was collected retrospectively from males diagnosed with non-obstructive 
azoospermia who underwent TESE procedure in the duration between May 2010 until June, 2018. The 
collected data includes the age of the patient, body mass index (BMI), testicular volume, hormonal 
profile (FSH LH, prolactin, testosterone), and the use of letrozole preoperatively. Logistic regression 
was done to address the association of these parameters to the sperm’s retrieval rate. 
Results: The study screaned 145 patients. Eighty patients fit the inclusion criteria and thus they were 
statistically analyzed. The use of letrozole was associated with negative TESE outcome (p=0.006), odd 
(0.154) CI 0.04-0.579. The other factors had no significant correlation to the TESE results. 
Conclusion: The evidence in this study showed an adverse effect of letrozole use on TESE results of those 
with high FSH. 
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1. Introduction 
Azoospermia is the complete absence of sperm in the ejaculate. It presents in about 1% of general 
population and 10-15% of the population seeking medical evaluation (Cavallini, Beretta, & Biagiotti, 
2011; Tiseo, Hayden, & Tanrikut, 2015).  
Azoospermia can be due to non-obstructive (NOA), or obstructive (OA) conditions. Furthermore, NOA 
is subdivided into primary (hypergonadotropic hypogonadism), and secondary (hypogonadotropic 
hypogonadism) (Cavallini, Beretta, & Biagiotti, 2011; Abdel Raheem et al., n.d.). 
Fertility chance for males with NOA may be improved by testicular exploration and sperm extraction 
methods (TESE or Micro TESE), where the extracted sperms are used for assistive reproduction methods 
like the in vitro fertilization Intracytoplasmic sperm injection (IVF-ICSI) (Abdel Raheem et al., n.d.).  
Therefore TESE combined with ICSI has been frequently used as a therapeutic procedure for treating 
NOA (Schlegel & Su, 1997).  
This study is designed to assess the effect of using letrozole before undergoing TESE procedure in males 
with NOA on the sperm retrieval rate. 
Letrozole is a non-steroidal substance that reversibly binds and inhibits aromatase enzyme, leading to an 
increase in the endogenous testosterone synthesis without any changes in the circulating estrogen. 
Inhibiting estrogen can strongly stimulates LH production, which in turn increases the intratesticular and 
circulating testosterone level, leading finally to an increase in the sperm production (Cavallini, Beretta, & 
Biagiotti, 2011; Ribeiro et al., 2016; Jarow & Zirkin, 2005).  
 
2. Study Design  
Data was collected retrospectively from males with NOA who underwent TESE procedure in the 
duration between May, 2010 until June, 2018, at Jordan University Hospital (JUH). Clinical profile for 
all patients includes patient’s age, testicular volume, hormonal profile (FSH, LH, testosterone and 
prolactin), duration of infertility and the use of letrozole pre- operatively. 
The eligible patients were those with NOA presented with the absence of spermatozoa in the ejaculate in 
two different occasions, elevated level of follicular stimulating hormone (FSH) above seven mIU/ml and 
a testicular volume of less than fifteen ml on scrotal ultrasonography using the three-diameter technique 
((length x width x height) x 0.71). 
On the other hand, patient with any of the conditions below was excluded: complete AZFa or AZFb 
microdeletions, Klinefelter syndrome, FSH level less than 7 mIU/ml with a testicular volume more than 
15 ml, severe systemic disease, hypogonadotropic hypogonadisms, complete retrograde ejaculation, or 
obstructive azoospermia which is manifested by a non-palpable vas deferens, history of vasectomy, or a 
dilated seminal vesicles. 
In this study the primary end point is to test the association between the use of letrozole prior to TESE 
and the SRR. The secondary end points were presented by the predictive value (P-value) for the variables; 
patient’s age, BMI, FSH level, and testicular volume on SRR.  
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The TESE procedure was done to all patients under general anesthesia, in which the testis is delivered 
through a median raphe incision, then a piece of the testicular tissue is taken from random incisions in 
each quadrant of the testis. If viable sperms are found in the collected tissue they are cryopreserved. 
The statistical software package IBM SPSS Statistics 21 was used for statistical analysis. Patient 
demographics were analyzed descriptively. To detect the independent predictors of favorable outcome 
Multivariate Logistic regression was used. P‐values were considered statistically significant if they were 
less than 0.05. 
 
3. Results 
The data of 143 patients were evaluated, a total of 63 were excluded; 54 had obstructive azoospermia, 5 
had hypogondotropic hypogonadism, 2 complete retrograde ejaculation, and 2 had Klinefelter 
syndrome. 
The remaining eighty patients involved in the study were classified according to the previous TESE 
results for two groups, “positive” with 45 patients (56.2%) and “negative” group with 35 patients 
(43.7%). The mean of age, BMI, testicular volume and hormonal profile were comparable in both 
groups (Table 1). 
 
Table 1. Demographic Data 
e lav p 
tsus rpE vT  
Positive( n= 35) Negative (n=45)  
Standard Deviation Mean Standard Deviation Mean  
0.673  7 34 6 35 Age 
0.195  3.7 28.0 3.9 29.2 BMI 
0.121  5 9 4 7 HL 
0.737  2 5 3 5 Testosterone 
0.349  5 11 12 11 Prolactine 
0.854  19 21 10 19 FSH 
0.426  4 9.8 3 10.2 esvaTprav TpETse var ltv ip 
 
A total of twenty two patients (27.5%) of both groups received letrozole 2.5 mg for three-month 
duration before undergoing TESE. data showed a negative SRR in 18 patients out of them, with only 4 
patients gaining positive results (Table 2). 
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Table 2. Patient Disposition 
 
TESE results 
Negative (n=45) Positive (n=35) 
Count N % Count N % 
pre op letrozole 
No 27 46.6% 31 53.4% 
Yes 18 81.8% 4 18.2% 
 
Regarding the predictive value of TESE outcome, logistic regression analysis (Table 3) showed 
statistical significance association between negative TESE outcome and the use of letrozole (p=0.006), 
odd (0.154) CI 0.04-0.579. The other factors had no significant correlation to the TESE results. 
 
Table 3. Binary Logistic Regression of the Association between the Age and the Infertility 
Duration of the Non‐Obstructive Azoospermic Patients and TESE Positive Outcome 
 B Sig. Odd 
95% C.I.for EXP(B) 
Lower Upper 
 
vpTrtltvp  Ep -1.874 .006 .154 .041 .579 
LH .107 .129 1.112 .969 1.277 
testosterone .073 .545 1.076 .849 1.362 
Prolactin -.017 .557 .983 .929 1.041 
FSH .002 .929 1.002 .962 1.043 
Age -.010 .817 .990 .906 1.081 
BMI -.045 .511 .956 .835 1.094 
 
4. Discussion  
Spermatogenesis is dependent on high intratesticular testosterone level, in addition to Sertoli cell 
stimulation. LH released by the anterior pituitary stimulates Leydig cells to increase Testosterone 
production which diffuses in the seminiferous tubules (Jarow & Zirkin, 2005; Walker & Cheng, 2005). 
Infertile men, especially those with non-obstructive azoospermia may have excess aromatase activity 
manifested by an increased serum T/E ratio (Schlegel, 2012). 
Pavlovich et al. (2001) advocate a cut-point of 10 as the lower limit of normal T/E ratios in men (the 
units used were: Testosterone in ng/dL, and estradiol in pg/mL). 
Medical therapy of infertile men aims to increase intratesticular testosterone and increase FSH 
production. Anastrazole (1 mg/day) and letrozole (2.5 mg/day)—an aromatase inhibitors—have been 
used in infertile men especially those with excess aromatase activity  
Letrozole causes an increase in both gonadotropin and androgen levels in the blood and a decrease in 
the estrogen level. Those parallel effects seem to improve spermatogenesis in NOA men.  
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In Literature review the effect of using letrozole vary according to the cause of infertility. In 
Oligospermic patients, many authors reported on the improvement of spermatogenesis following the 
use of letrozole (Jarow & Zirkin, 2005; Walker & Cheng, 2005; Schlegel, 2012). Besides that, there are 
collaporating reports on letrozole efficacy in restoration of active spermatogenesis in azospermic men 
(Gregoriou et al., 2012; Patry et al., 2009; Saylam, Efesoy, & Cayan, 2011; Zhao et al., 2014; Kyrou et 
al., 2014). Table 4 summerizes the reports on letrozole effect in azospermic men.  
 
Table 4. Summary of the Reports on Letrozole Effect on NOA Patients 
Outcome after letrozole use Included patients Study type Reference  
The patient was converted to active spermatogenesis 
after 4 months of lezotrole use. 
He remained azoospermic because of his simultaneous 
obstruction at the level of the epididymis. 
 1 NOA patient 
 normal FSH 
 T/E <10  
case report 
Patry et 
al. 
Out of the 17 azoospermic patient, 4 (23.5%) 
presented spermatozoa in the ejaculate, while 13 
(76.5%) remained azoospermic after letrozole 
treatment 
 17 NOA patient 
 10 oligospermia patient 
 No comment on FSH 
 T/E <10 
 All treated with letrozole 
prospective  
Saylam et 
al. 
After taking letrozole for 3 months, semen analyses by 
computer-aided sperm analysis (CASA) revealed 
normal spermatogenesis 
 1 NOA patient 
 high FSH 
 T/E <10 
case report 
Zhao et 
al. 
Both were treated with letrozole for a period of 4 
months (2.5 mg/48 h), resulting in normal 
spermatogenesis 
 2 NOA patient 
 normal FSH 
 T/E <10 
case report 
Kyrou et 
al. 
Spermatozoa were found in the ejaculate of all the 
NOA patients treated with letrozole for 3 months, 
while no spermatozoa could be found in the ejaculate 
of the NOA patients treated with placebo.  
 11 NOA patient  
 6 treated with letrozole, 5 
treated with placebo 
 T/E <10 
prospective  
Cavallini, 
2013  
 
Our result was contradictory to the previously published reports, in which letrozole use in the NOA had 
negative impact on spermatogenesis. 
Out of the 80 patients in the current study, 22 patients were treated with letrozole. Only 4 (18.1%) had 
positive results. logistic regression analysis revealed significant association between the use of 
letrozole and the negative results (p=0.006), odd (0.154) CI 0.04-0.579. 
Most of the previous reports were on patients with normal FSH. However, in our study the mean of 
FSH is 20.2 mIU/ml. This may indicate that the patient with normal FSH are most likely to benefit 
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from letrozole than those with high FSH.  
Regarding the other parameters and their effect on SRR, The age was not found to have predictive 
value by Amer et al. (2018) and Ramasamy et al. (2014). 
Furthermore, Bryson et al. (2014), Amer et al. (2018) and Li et al. (2017) observed that testicular 
volume of NOA patients did not affect the sperm retrieval rate (SRR). 
While Ishikawa (2012) reported that the serum FSH could predict the TESE results, Li et al. (2017) 
found that FSH possessed low predictive values. 
Our data demonstrated that neither age, BMI, serum FSH level nor testicular volume could predict the 
sperm retrieval rate when evaluated as the sole independent predictive factor. 
The limitation of this study resides in it’s nature as retrospective study as well as to the small sample 
size. We think that further researches are needed to evaluate the effect of letrozole in NOA men 
especially those with high FSH level. 
 
5. Conclusion 
The evidence in this study showed an adverse effect of letrozole use on TESE results of those with high 
FSH. Further researches are needed to address the patient’s criteria who may benefit from this 
treatment. 
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